Complications of Anti-Vascular Endothelial Growth Factor Drugs

Author(s): Michael Tolentino

Journal Name: Current Drug Therapy

Volume 7 , Issue 2 , 2012

Become EABM
Become Reviewer
Call for Editor


The development of anti-vascular endothelial growth factor (VEGF) therapy is both revolutionary and unprecedented in the history of ophthalmology. In the past ophthalmic drugs have been the reformulations of previously well characterized systemic drugs. Anti-VEGF therapies for retinal diseases represent the first time that systemic and ocular complications are being initially defined by the ophthalmic profession. The purpose of this chapter is to review both the described and potential complications of Anti-VEGF therapies. This chapter will describe obvious associated complications such as endophthalmitis and elevated intraocular pressure and non obvious complications such as exacerbation of hypertension, increased risk of thromboembolic events, renal thrombosis and issues with surgical wound healing.

Keywords: Age-related macular degeneration, intravitreal injections, vascular endothelial growth factor, VEGF, treatment, physiology, Endophthalmitis, Ganglion Cell Changes, Geographic Atrophy, Vitreous Hemorrhage

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Published on: 17 May, 2012
Page: [131 - 137]
Pages: 7
DOI: 10.2174/157488512800675959
Price: $65

Article Metrics

PDF: 10